More on CAMX
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $36.06 |
|
|||
| Open | $35.87 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $35.87 | ||||
| Day Low | $35.87 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 33 | ||||
- Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA
- Camurus (CAMX) announces expansion of Lilly collaboration, decision extends Lilly's exclusive, global rights to Camurus' FluidCrystal technology
- Camurus announces expansion of Lilly collaboration
- FDA accepts Camurus resubmission for acromegaly treatment Oclaiz
- Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly
- Camurus reports positive topline results for CAM2056, semaglutide monthly depot
Entities mentioned with CAMX
- FDA | View Related Stories »
- PDUFA | View Related Stories »
- AdCom | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Jefferies & Co | View Related Stories »
- Show More...
